Sarepta Therapeutics Announces Incentive Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetics for rare diseases, granted equity awards on August 30, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of the Board of Directors under Sarepta’s 2024 Employment Start Incentive Plan. The Equity Awards are intended to serve as a material incentive for the employment of 20 individuals hired by Sarepta in August 2024. The Equity Awards were approved under Nasdaq Listing Rule 5635(c)(4).

Employees received a total of 9,290 restricted stock units (“RSUs”). One-quarter of the RSUs vest annually on each anniversary of the grant date, such that the RSUs granted to each employee will fully vest on the fourth anniversary of the grant date, provided that the employee continues to be employed by Sarepta on such vesting date. Employees were not granted options to purchase shares of Sarepta’s common stock.